Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

576 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunological differences between primary and metastatic breast cancer.
Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Pusztai L. Szekely B, et al. Among authors: pusztai l. Ann Oncol. 2018 Nov 1;29(11):2232-2239. doi: 10.1093/annonc/mdy399. Ann Oncol. 2018. PMID: 30203045 Free article.
Gene expression profiling of primary breast cancer.
Rouzier R, Wagner P, Morandi P, Pusztai L. Rouzier R, et al. Among authors: pusztai l. Curr Oncol Rep. 2005 Jan;7(1):38-44. doi: 10.1007/s11912-005-0024-y. Curr Oncol Rep. 2005. PMID: 15610685 Review.
Breast cancer biomarkers.
Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Ross JS, et al. Among authors: pusztai l. Adv Clin Chem. 2005;40:99-125. doi: 10.1016/s0065-2423(05)40003-7. Adv Clin Chem. 2005. PMID: 16355921 Review.
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.
Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M. Yang CH, et al. Among authors: pusztai l. Ann Oncol. 2006 May;17(5):813-7. doi: 10.1093/annonc/mdj131. Epub 2006 Jan 10. Ann Oncol. 2006. PMID: 16403809 Free article. Clinical Trial.
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L. Mazouni C, et al. Among authors: pusztai l. Ann Oncol. 2007 May;18(5):874-80. doi: 10.1093/annonc/mdm008. Epub 2007 Feb 10. Ann Oncol. 2007. PMID: 17293601 Free article. Clinical Trial.
576 results